SAB Biotherapeutics Inc (NASDAQ:SABS) saw its stock surge by 33% following the announcement of a $175 million private placement backed by a mix of strategic and institutional investors. The ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Betterware de Mexico SAB de CV (BWMX) declares $0.3252/share quarterly dividend, 6.2% increase from prior dividend of $0.3063 ...

On Tuesday, SAB BIO (NASDAQ:SABS) released topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers. The study met its primary safety and pharmacodynamic ...

Betterware de Mexico SAB de CV shares have risen 22% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $17.31, a climb of 72% in the last 12 ...

SAB plans to be listed on NASDAQ following the closing of the transaction. The proposed transaction implies an enterprise value for SAB, on a post-merger basis, of approximately $325 million (assuming ...

The FDA has granted Breakthrough Therapy Designation (BTD) to SAB Biotherapeutics Inc's (NASDAQ:SABS) SAB-176, an investigational therapy for post-exposure prophylaxis for Type A and Type B influenza ...

Positive clinical results confirm that SAB’s fully-human polyclonal antibodies can be broadly neutralizing to both known and unknown viral variants—a valuable feature when addressing rapidly mutating ...

Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 ...